Davy James, Managing Editor

Despite inducing anti-HIV antibodies, vaccine in HVTN 505 trial still not protective.

One confirmed case and one probable case of definite progressive multifocal leukoencephalopathy reported in patients taking Gilenya for MS.

Study finds significant barriers to health care access, including stigmatization.

Pharmacy expenditures account for 20% of total care costs for children with hemophilia.

Michael Zeglinski, Vice President of Specialty Pharmacy Operations at BriovaRx, discusses whether the R&D cost for biosimilars will affect the overall cost reduction.

Elevated risk found for heart arrhythmia, specifically atrial fibrillation.

Top stories of the week on Specialty Pharmacy Times.

Lithium chloride found to slow degradation.

Liver damage progresses at a more rapid pace in patients with HIV.

Toradol may limit ability of tumor cells to grow and spread.

Study finds 80% of people with cardiovascular disease significantly underuse statins.

Iressa blocks the activity of an enzyme responsible for regulating pathways implicated in the growth and survival of cancer cells.

Study finds that $1 out of every $9 spent on health care is wasted due to non-adherence.

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses takeaways from the impact of high cost drug launches on specialty pharmacy.

Compound reduces residual levels from infected dormant cells.

Top stories of the week on Specialty Pharmacy Times from July 20 to 24.

Colonoscopy can catch tumors in a more treatable stage.

Cholesterol-lowering drug is expected to cost between $7,000 and $12,000 annually.

Technivie with ribavirin is the first drug to demonstrate safety and efficacy in genotype 4 infections without interferon.

Sonidegib treats adult patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy.

Company alleges insurers are taking advantage of program to shift cost of Sovaldi.

The FDA today approved the first cholesterol-lowering PCSK9 inhibitor alirocumab (Praluent).

PCSK9 inhibitors could cost up to $23.3 billion nationally if widely prescribed.

Joseph Morse, president and chief operating officer of Therigy, LLC, discusses how specialty pharmacies can best utilize data analytics.

New procedure seeks to guide therapeutic decisions.

Treating hepatitis C patients who receive health care through Medicaid with Sovaldi could exceed $55 billion.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses methods to improve patient access to specialty medications.

Targeting protein that helps cancer cells survive chemotherapy shows promise.

Stopping smoking extends survival by nearly a year.

Top stories of the week on Specialty Pharmacy Times from July 13 to July 17.